Jasper Therapeutics (JSPR) Proxy filing summary

Executive summary

• Annual meeting scheduled for July 31, 2026, to be held virtually at 10:00 a.m. Pacific Time.

• Proxy materials, including the 2026 Proxy Statement and 2025 Annual Report, are available online for review.

• Stockholders can vote electronically before or during the meeting using a control number.

Voting matters and shareholder proposals

• Election of two Class II directors to serve until the 2029 annual meeting.

• Advisory vote on the compensation of named executive officers.

• Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year ending December 31, 2026.

• Board recommends voting "FOR" all nominees and proposals.

Board of directors and corporate governance

• Two Class II director positions are up for election, with terms extending to 2029.